Co announces that the U.S. FDA has accepted for filing the application by its partner, GlaxoSmithKline (GSK), for REQUIP XL 24-Hour Extended-Release Tablets, the proposed brand name for a once-daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results